Human Genome Sciences, Inc.

Delta Biotechnology Limited

Other

Novozymes Biopharma Dk A/s

William A Haseltine

Craig A Rosen

Steven M Ruben

Ying-Fei Wei

Mark D Adams

Claire M Fraser

Ewen F Kirkness

Robert D Fleischmann

Rebecca A Fuldner

David James Ballance

Andrew J Turner

Guo-Liang Yu

Steve Ruben

Bert Vogelstein

Kenneth W Kinzler

Nicholas C Nicolaides

Paul A Moore

Nickolas Papadopoulos

David W LaFleur

David William Lafleur

Jason B Bock

Andrew John Turner

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

Albumin fusion proteins

G-CSF-albumin fusion proteins

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating or preventing diseases, disorders or conditions related to diabetes mellitus using albumin fusion proteins of the invention.

Growing community of inventors

Washington, DC, United States of America

William A Haseltine